Midostaurin

N/A

Report date: 2026/02/12 20:00:14
NMEFirst In Class

Base Information

Drug NameMidostaurin
Drug Alias Name米哚妥林N-benzoyl-staurosporine4-N-benzoyl staurosporine米多滔林Benzoylstaurosporine +[13] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProtein kinase C alpha inhibitorsVascular endothelial growth factor receptor 2 antagonistsStem cell growth factor receptor inhibitors +[5] 
TargetsStem cell growth factor receptorProtein kinase C alphaPlatelet-derived growth factor receptor beta +[5] 
Therapy Area/IndicationsMyelodysplastic SyndromesHepatic InsufficiencyHematologic Neoplasms +[9] 
Global Approved IndicationsHematologic NeoplasmsMastocytosis, SystemicMastocytosis +[5] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2017/04/28
Country/TerritoryCzechiaBelgiumBulgaria +[33] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesNovartis Pharma AgNovartis Pharmaceuticals CorpNovartis Europharm Ltd
Inactive CompaniesUniversity Medical Center GroningenWashington University School Of MedicineStanford University +[9] 
Active IndicationsHematologic NeoplasmsMastocytosis, SystemicMastocytosis +[5] 
Inactive IndicationsMyelodysplastic SyndromesHepatic InsufficiencyPrecursor Cell Lymphoblastic Leukemia-Lymphoma +[4] 

Other Information

ATC CodeL01EX10
Related LinksWikipediaDrugBankKEGG